Send us Feedback

Osiris Therapeutics (OSIR)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

OSIR » Topics » FORM 10-Q

This excerpt taken from the OSIR 10-Q filed May 11, 2009.

FORM 10-Q

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

For the quarterly period ended March 31, 2009

 

 

 

or

 

 

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                     to                    

 

This excerpt taken from the OSIR 10-Q filed Nov 10, 2008.

FORM 10-Q

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended September 30, 2008

 

 

or

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

This excerpt taken from the OSIR 10-Q filed Aug 11, 2008.

FORM 10-Q

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended June 30, 2008

 

or

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from                     to

 

This excerpt taken from the OSIR 10-Q filed May 12, 2008.

FORM 10-Q

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended March 31, 2008

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from                     to                    

 

This excerpt taken from the OSIR 10-Q filed Nov 13, 2007.

FORM 10-Q

 

 

x

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the quarterly period ended September 30, 2007

 

 

o

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the transition period from                     to                    

 

This excerpt taken from the OSIR 10-Q filed Aug 10, 2007.

FORM 10-Q

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended June 30, 2007

 

 

Commission file number— 001-32966

 

 

This excerpt taken from the OSIR 10-Q filed May 14, 2007.

FORM 10-Q

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended March 31, 2007

Commission file number— 001-32966

This excerpt taken from the OSIR 10-Q filed Nov 13, 2006.

FORM 10-Q

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended September 30, 2006

 

Commission file number—001-32966

 

This excerpt taken from the OSIR 10-Q filed Sep 15, 2006.

FORM 10-Q

 

x

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

 

o

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For The Quarterly Period Ended June 30, 2006

 

Commission file number — 001-32966

 

EXCERPTS ON THIS PAGE:

10-Q
May 11, 2009
10-Q
Nov 10, 2008
10-Q
Aug 11, 2008
10-Q
May 12, 2008
10-Q
Nov 13, 2007
10-Q
Aug 10, 2007
10-Q
May 14, 2007
10-Q
Nov 13, 2006
10-Q
Sep 15, 2006

RELATED TOPICS for OSIR:

"FORM 10-Q" elsewhere:

ACADIA Pharmaceuticals (ACAD)
Affymax (AFFY)
AGENUS INC (AGEN)
ARIAD Pharmaceuticals (ARIA)
BioCryst Pharmaceuticals (BCRX)
Corcept Therapeutics (CORT)
Curis (CRIS)
EPIX Pharmaceuticals (EPIX)
EXACT Sciences (EXAS)
GTC Biotherapeutics (GTCB)
IGI (IG)
ImmunoGen (IMGN)
Inhibitex (INHX)
InterMune (ITMN)
Metabasis Therapeutics (MBRX)
Molecular Insight Pharmaceuticals (MIPI)
Biota Pharmaceuticals, Inc. (NABI)
Neose Technologies (NTEC)
Neurobiological Technologies (NTII)
Pharmacopeia Drug Discovery (PCOP)
Progenics Pharmaceuticals (PGNX)
Polydex Pharmaceuticals (POLXF)
Peregrine Pharmaceuticals (PPHM)
Sangamo BioSciences (SGMO)
Savient Pharmaceuticals (SVNT)
AmpliPhi Biosciences Corp (TGEN)
Theravance (THRX)
SYNAGEVA BIOPHARMA CORP (TRMS)
Vical (VICL)
Vanda Pharmaceuticals (VNDA)
XenoPort (XNPT)
XOMA (XOMA)
CORD BLOOD AMERICA (CBAI)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki